 | | Vol. 11.30 – 14 August, 2020 |
| |
|
|
| In prostate cancer cells, EGR3 blocked the epithelial-to-mesenchymal transition process and suppressed cell migration and invasion.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Hepatocyte growth factor activator inhibitor-2 overexpression could suppress the induction effect of TMPRSS2 on pro-HGF activation and prostate cancer cell invasion.
[Oncogene] |
|
|
|
| Researchers identified capping proteins CAPZA1 and CAPZB2 as PIM1 substrates, and showed that phosphorylation of either of them led to increased adhesion and migration of human prostate cancer cells.
[Cell Communication and Signaling] |
|
|
|
| Investigators demonstrated DNA methyltransferases DNMT1 and DNMT3B were highly abundant in prostate cancer cells, yet these DNMTs bound primarily to the transcription suppressor in DU145.
[Carcinogenesis] |
|
|
|
| Scientists investigated the mechanisms of the anti-cancer effects of astaxanthin on prostate cancer cell lines using aggressive prostate cancer DU145 cells.
[Marine Drugs] |
|
|
|
| Small nucleolar RNA host gene 6 (SNHG6) expression was increased and miR-186 expression was reduced in drug-resistant prostate cancer tissues and cells.
[Cancer Cell International] |
|
|
|
| The analysis of nuclear morphology of PC3 cells treated with triterpene-enriched fraction increased the number of cells with large and regular nuclei suggesting senescence induction, which was supported by β-galactosidase overexpression.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Elevated levels of LINC00992 and GOLM1 were detected in prostate cancer tissues and cells. LINC00992 exerted facilitating functions in prostate cancer cell proliferation and migration.
[BMC Cancer] |
|
|
|
| Epigallocatechin-3-gallate (EGCG) induced an internal Ca2+ increase in prostate cancer (PCa) cells by a multi-step mechanism. Researchers confirmed the possibility of using EGCG as a synergistic adjuvant in combined therapies for recalcitrant malignancies like androgen-independent PCa.
[Life Sciences] |
|
|
|
| Scientists used proteomics approaches to investigate the secreted proteins of paired human androgen-repressed prostate cancer cell lines, representing the epithelial and mesenchymal phenotypes.
[PLoS One] |
|
|
|
|
| The authors discuss the underlying mechanism of electroporation and an overview of the latest progress and development perspectives of electroporation-based treatments in urology.
[Cancers] |
|
|
|
|
| Cancer Targeted Technology (CTT) announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial.
[Cancer Targeted Technology, Inc.] |
|
|
|
|
| November 2 – November 3
Virtual |
|
|
|
|
|
| | Rutgers Cancer Institute of New Jersey – Rutgers, New Jersey, United States |
|
|
|
| | West Virginia University – Morgantown, West Virginia, United States |
|
|
|
| | European Molecular Biology Laboratory – Hinxton, Cambridge, United Kingdom |
|
|
|
| | University of Maryland, Baltimore – Baltimore, Maryland, United States |
|
|
|
| | Stanford Institute for Stem Cell Biology and Regenerative Medicine – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
